Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apixaban versus enoxaparin for postoperative venous thromboembolism prophylaxis after gynecologic or colorectal cancer surgery
IRCT20230419057967N1Phase 3Completed
- Sponsor
- Baqiyatallah University of Medical Sciences
- Start
- Jan 2024
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial in venous thromboembolism (VTE) comparing Apixaban extended prophylaxis with Enoxaparin extended prophylaxis (2 arms). Primary endpoint: Incidence of major bleeding or clinically relevant non-major bleeding. Started Jan 2024; status: completed.
02
Drugs
apixabanenoxaparinheparin
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on IRCT20230419057967N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20230419057967N1.